Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 30, Issue 12, Pages 1321-1328Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2011.37.8133
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [R01-CA083855, R01-CA102776, T32-GM07170]
- University of Pennsylvania School of Medicine
- Cancer Genetics Network
- National Cancer Institute [P30-CA051008-17]
- National Institute for Health Research
- Royal Marsden National Health Service (NHS) Foundation Trust
- Cancer Research United Kingdom [C5047/A8385]
- Tepnel (Gen-Probe)
- Vista Diagnostics
- Illumina
- Cancer Research UK [15007] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0510-10096] Funding Source: researchfish
Ask authors/readers for more resources
Purpose Mutations in BRCA1/2 dramatically increase the risk of both breast and ovarian cancers. Three mutations in these genes (185delAG, 5382insC, and 6174delT) occur at high frequency in Ashkenazi Jews. We evaluated how these common Jewish mutations (CJMs) affect cancer risks and risk reduction. Methods Our cohort comprised 4,649 women with disease-associated BRCA1/2 mutations from 22 centers in the Prevention and Observation of Surgical End Points Consortium. Of these women, 969 were self-identified Jewish women. Cox proportional hazards models were used to estimate breast and ovarian cancer risks, as well as risk reduction from risk-reducing salpingo-oophorectomy (RRSO), by CJM and self-identified Jewish status. Results Ninety-one percent of Jewish BRCA1/2-positive women carried a CJM. Jewish women were significantly more likely to undergo RRSO than non-Jewish women (54% v 41%, respectively; odds ratio, 1.87; 95% CI, 1.44 to 2.42). Relative risks of cancer varied by CJM, with the relative risk of breast cancer being significantly lower in 6174delT mutation carriers than in non-CJM BRCA2 carriers (hazard ratio, 0.35; 95% CI, 0.18 to 0.69). No significant difference was seen in cancer risk reduction after RRSO among subgroups. Conclusion Consistent with previous results, risks for breast and ovarian cancer varied by CJM in BRCA1/2 carriers. In particular, 6174delT carriers had a lower risk of breast cancer. This finding requires additional confirmation in larger prospective and population-based cohort studies before being integrated into clinical care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available